HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Leibowitz, M. Articles by Walker, R. Search for Related Content PubMed PubMed Citation Articles by Leibowitz, M. Articles by Walker, R.

Long-term treatment with pergolide

Decreased efficacy with time

From the New York University School of Medicine, New York, NY.

We studied the effect of pergolide (combined with levodopa) in 17 patients with Parkinson's disease, including 15 with "wearing off" or on-off phenomena, who had been taking pergolide for at least 2 years. Mean duration of the study was 27.8 months. All 17 patients improved initially, but the improvement later faded. Mean disability score, which decreased initially by 60% (significant), was decreased only by 20% after 2 years (not significant). Wearing off and on-off phenomena, which improved initially, became prominent again. Four patients lost all the improvement, nine patients lost much of the improvement, and four maintained much of the improvement. Mean dose of pergolide was 2.2 mg (range, 0.8 to 5.0 mg).

Address correspondence and reprint requests to Dr. Lieberman, 530 First Avenue, N.B. 7W15, New York, NY 10016.

Supported in part by a grant from Eli Lilly and Company, Indianpolis, IN.

Presented in part at the thirty-fifth annual meeting of the American Academy of Neurology, San Diego, CA, April 1983.

Accepted for Publication May 10, 1983.